Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe

China investigates after vaccine suspected in seven deaths

Source: Reuters - Mon, 23 Dec 2013 10:33 AM
Author: Reuters
hum-peo med-dev
Tweet Recommend Google + LinkedIn Bookmark Email Print
Leave us a comment

BEIJING, Dec 23 (Reuters) - Chinese health authorities are investigating after seven infants died following inoculation with a hepatitis B vaccine, state media reported on Monday.

China has been beset by a series of product safety scandals over the past few years.

At least six children died in 2008 after drinking milk contaminated by the industrial chemical melamine, and there have also been reports of children dying or becoming seriously ill from faulty encephalitis, hepatitis B and rabies vaccines.

State news agency Xinhua said that of the seven deaths from the hepatitis B vaccine in the latest case, four were in the southern province of Guangdong. The other cases were in the provinces of Hunan and Sichuan.

The official China Daily said that all hospitals using the vaccine, made by Shenzhen-based BioKangtai, had been ordered to take it off their shelves while the Health Ministry investigates the company's products and the deaths.

The company said in a statement last week, carried by state media, said that it rigorously followed safety rules but that they were testing the batches suspected of causing the deaths.

The topic has been widely discussed on China's popular Twitter-like microblogging service Sina Weibo, with many people worried about the safety of China's vaccines and calling on the government to make more information public.

"Why was this allowed onto the market? The government needs to come clean about this," wrote one Weibo user.

Many Chinese people are suspicious that the government tries to cover up bad news about health problems, despite assurances of transparency. In 2003, the government initially tried to cover-up the outbreak of the SARS virus. (Reporting by Ben Blanchard and Hui Li; Editing by Robert Birsel)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs